U.S. markets closed
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow 30

    28,725.51
    -500.10 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.89 (-1.51%)
     
  • Russell 2000

    1,664.72
    -10.21 (-0.61%)
     
  • Crude Oil

    79.74
    -1.49 (-1.83%)
     
  • Gold

    1,668.30
    -0.30 (-0.02%)
     
  • Silver

    19.01
    +0.30 (+1.62%)
     
  • EUR/USD

    0.9801
    -0.0018 (-0.19%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • GBP/USD

    1.1166
    +0.0043 (+0.38%)
     
  • USD/JPY

    144.7200
    +0.2770 (+0.19%)
     
  • BTC-USD

    19,142.64
    -169.97 (-0.88%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Read Why Aeglea BioTherapeutics Shares Are Skyrocketing Today?

·1 min read
  • The European Medicines Agency (EMA) has validated Aeglea BioTherapeutics Inc's (NASDAQ: AGLE) marketing application seeking approval for pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D).

  • Arginase deficiency is an inherited disorder that causes the amino acid arginine (a building block of proteins) and ammonia to accumulate gradually in the blood.

  • Ammonia, formed when proteins are broken down in the body, is toxic if levels become too high.

  • Related: Aeglea BioTherapeutics Shares Plummet Following Refusal To File Letter From FDA.

  • Patients experience severe spasticity-related mobility limitations, seizures, developmental delay, intellectual disability, and early mortality.

  • The application was submitted by Immedica Pharma AB, Aeglea's commercialization partner in Europe and the Middle East.

  • The EMA has granted pegzilarginase orphan drug designation.

  • Immedica's submission includes data from multiple clinical studies, including the PEACE Phase 3 study and its ongoing long-term extension, a Phase 1/2 trial, and an open-label extension study.

  • Results showed that pegzilarginase could rapidly and sustainably lower arginine levels and improve mobility.

  • In the PEACE study, most treatment-emergent adverse events were mild or moderate, and there were no discontinuations due to treatment-emergent adverse events.

  • Price Action: AGLE shares are up 72.71% at $0.87 during the premarket session on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.